Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Intrapatient Dose Titration Study of KER-047 in Participants With Functional Iron Deficiency Anemia Associated With Myelodysplastic Syndromes, Myelofibrosis, and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

NCT05927012 is registered in ClinicalTrials.gov with Keros Therapeutics, Inc. as lead sponsor.

NCT NCT05927012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05927012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Intrapatient Dose Titration Study of KER-047 in Participants With Functional Iron Deficiency Anemia Associated With Myelodysplastic Syndromes, Myelofibrosis, and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Lead sponsor
Keros Therapeutics, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2023
Completion date
January 4, 2026
Enrollment
0 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

iron deficiency anemia